LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Interest Income
Income earned on cash, deposits, and investments held by the company.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $2.64M rose 13.8% year over year, ahead of the -0.1% change in trailing-twelve-month interest income. Sequentially, it fell 11.5% from the prior quarter.
Context
- Interest income amounted to 51.1% of revenue in FY2025.
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +13.8% holds above the trailing-twelve-month pace of -0.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 9.76M USD
- Year-over-year change
- +14.1%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.76M | +14.1% |
| FY2024 | 2024-12-31 | 8.55M | +290.7% |
| FY2023 | 2023-12-31 | 2.19M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Interest Income vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.1% is the 4th highest of 10, against a peer median of -31.7%.
- Interest income amounts to 48.0% of revenue for LENZ, versus a peer median of 5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $20.72M USD | +7.0% | +117.2% | 9.9% | |
| LTM Mar 2026 | $16.38M USD | -20.2% | +92.8% | 8.4% | |
| LTM Mar 2026 | $11.81M USD | -31.7% | +52.0% | — | |
| LTM Mar 2026 | $10.08M USD | -0.1% | — | 48.0% | |
| LTM Mar 2026 | $5.77M USD | +13.6% | +309.2% | — | |
| LTM Mar 2026 | $4.98M USD | +23.6% | — | 123.4% | |
| LTM Mar 2026 | $3.72M USD | -43.7% | +3516.4% | — | |
| LTM Mar 2026 | $3.69M USD | -40.9% | +22.9% | 1.9% | |
| LTM Mar 2026 | $2.32M USD | -61.0% | +45.2% | — | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $1.97M USD | — | — | 2.0% |
| FY2025 | €985K EUR | -62.5% | +56.7% | 3.3% | |
| Peer median (excluding LENZ) | — | -31.7% | +74.7% | 5.8% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| Weighted Avg Shares | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
| Weighted Avg Shares (Diluted) | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.